Innovative Drug Development in Dermatology
Latest News

April 1, 2015

Brickell Signs Exclusive License and Development Agreement for its novel, topical soft-anticholigenric, BBI-4000, with Kaken Pharmaceutical Co., Ltd. in Japan.

Read Article (PDF)

Focused on the development of novel therapies for the treatment of skin diseases.

Brickell Biotech, Inc. is a clinical-stage pharmaceutical company focused on the development of innovative, first-in-class therapeutics to satisfy current unmet human needs in the global dermatology markets.



Brickell Biotech, Inc. © 2015 All Rights Reserved.